Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı

Atalay, Eray; YAŞAR, Erdoğan; yildirim, nilgün

doi:10.4274/tjo.galenos.2018.06887

Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı

Erdoğan YAŞAR, (Aksaray Üniversitesi, Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, Aksaray, Türkiye)

Nilgün YILDIRIM, (Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Eskişehir, Türkiye)

Eray ATALAY (Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Eskişehir, Türkiye)

Türk Oftalmoloji Dergisi

15 1

Yıl: 2019 Cilt: 49 Sayı: 1 Sayfa Aralığı: 1 - 5 Metin Dili: Türkçe DOI: 10.4274/tjo.galenos.2018.06887 İndeks Tarihi: 10-11-2020

Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı

Öz:

Amaç: Psödoeksfoliasyon sendromu (PES) ile antidepresan ilaç kullanımı arasındaki ilişkiyi araştırmaktır.Gereç ve Yöntem: Eskişehir’de PES sıklığının saptanması amacıyla yapılan bir epidemiyolojik çalışma için Türkiye İstatistikKurumu tarafından randomize seçilen 2356 kişiden 2017’si çalışmaya katıldı. Muayene sırasında hekim tanılı sistemik hastalıklar veilaç kullanımının belirlenmesi amacıyla ayrıntılı bir anket uygulaması yapıldı.Bulgular: Çalışmaya katılan 2017 kişinin 8’i çeşitli sebeplerle (2 posterior sineşili, 2 kornea opasitesi,1 kooperasyon yetersizliği, 1tek gözlülük, 1 aktif adenoviral konjonktivit ve 1 dar açılı glokom öyküsü) çalışma dışı bırakıldı. Verileri analiz edilen 2009 kişiden100’ünde (%5) PES saptandı. Antidepresan ilaç kullanım sıklığı PES (-) glokomu olmayan grupta %1,1 (n=21), PES (+) glokomuolmayan grupta ise %4,1 (n=3) olarak tespit edildi. Her iki grup arasındaki fark istatistiksel olarak anlamlı idi (p=0,024). Ayrıcaantihipertansif (p<0,001) ve koroner arter hastalığı (p=0,009) için ilaç kullanımı da PES grubunda yüksek saptandı.Sonuç: Antidepresan ilaç kullanım sıklığının PES grubunda yüksek bulunmasının sebebi PES ve depresyonun her ikisinin patogenezindede ortak olan vasküler hasar ve enflamatuvar proçesler dışında kronik sistemik hastalıkların da yüksek bulunması ile ilgili olabilir.

Anahtar Kelime:

Pseudoexfoliation Syndrome and Antidepressant Drug Use

Öz:

Objectives: To investigate the relationship between pseudoexfoliation syndrome (PES) and the use of antidepressant medications. Materials and Methods: This population-based, cross-sectional study included 2,017 of 2,356 invited subjects who were randomly selected from the Turkish Statistical Institute database (www.turksat.gov.tr/) as part of an epidemiologic study which specifically aimed to detect the prevalence of PES in the province of Eskişehir. During the examination, a detailed questionnaire was administered to determine physician-diagnosed systemic disease and drug use. Results: Eight of the 2,017 participants in the study were excluded for various reasons (2 with posterior synechiae, 2 with corneal opacity, 1 uncooperative patient, 1 eviscerated patient, 1 with active adenoviral keratoconjunctivitis, and 1 with a history of angle closure). PES was detected in 100 (5%) of the 2,009 patients whose data were analyzed. The percentage of subjects with concurrent antidepressant drug use in the PES and non-PES non-glaucoma groups were 4.1% (n=3) and 1.1% (n=21), respectively. The difference between the two groups was statistically significant (p=0.024). In addition, the use of medications for hypertension (p<0.001) and coronary artery disease (p=0.009) was also higher in the PES group. Conclusion: The higher prevalence of antidepressant drug use in patients with PES may be related to the processes of vascular damage and inflammation common to the pathogenesis of both PES and depression, as well as the high rate of chronic systemic comorbidities in these patients.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Yıldırım N. Psödoeksfoliasyon glokomunda moleküler patofizyoloji. Türkiye Klinikleri J Ophtalmol-Special Topics. 2012;5:24-29.
2. Schlotzer-Schrehardt UM, Koca MR, Naumann GO, Volkholz H. Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch Ophthalmol. 1992;110:1752-1756.
3. Streeten BW, Li ZY, Wallace RN, Eagle RC Jr, Keshgegian AA. Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch ophthalmol. 1992;110:1757-1762.
4. Naumann GO, Schlötzer-Schrehardt U, Küchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist. Intraocular and systemic manifeastations. Ophtahalmology. 1998;105;951-968.
5. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
6. Moreno-Montanes J, Lajara Blesa J. IgG, albumin and total IgG index in the aqueous humour of eyes with pseudoexfoliation syndrome. Acta Ophthalmol Scand. 1995;73:249-251.
7. Berlau J, Lorenz P, Beck R, Makovitzky J, Schlötzer-Schrehardt U, Thiesen HJ, Guthoff R. Analysis of aqueous humour proteins of eyes with and without pseudoexfoliation syndrome. Graefes Arch Clin Exp Ophthalmol. 2001;239:743-746.
8. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol. 1997;124:685-687.
9. Shimizu T. Changes of iris vessels in capsular glaucoma: three dimensional and electron microscopic studies. Jpn J Ophtalmol. 1985;29:434-452.
10. Schumacher S, Schlötzer-Schrehardt U, Martus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2001;357:359-360.
11. Aung T, Ozaki M, Lee MC, Schlötzer-Schrehardt U, Thorleifsson G, Mizoguchi T, Igo RP Jr, Haripriya A, Williams SE, Astakhov YS, Orr AC, Burdon KP, Nakano S, Mori K, Abu-Amero K, Hauser M, Li Z, Prakadeeswari G, Bailey JNC, Cherecheanu AP, Kang JH, Nelson S, Hayashi K, Manabe SI, Kazama S, Zarnowski T, Inoue K, Irkec M, Coca-Prados M, Sugiyama K, Järvelä I, Schlottmann P, Lerner SF, Lamari H, Nilgün Y, Bikbov M, Park KH, Cha SC, Yamashiro K, Zenteno JC, Jonas JB, Kumar RS, Perera SA, Chan ASY, Kobakhidze N, George R, Vijaya L, Do T, Edward DP, de Juan Marcos L, Pakravan M, Moghimi S, Ideta R, Bach-Holm D, Kappelgaard P, Wirostko B, Thomas S, Gaston D, Bedard K, Greer WL, Yang Z, Chen X, Huang L, Sang J, Jia H, Jia L, Qiao C, Zhang H, Liu X, Zhao B, Wang YX, Xu L, Leruez S, Reynier P, Chichua G, Tabagari S, Uebe S, Zenkel M, Berner D, Mossböck G, Weisschuh N, Hoja U, Welge-Luessen UC, Mardin C, Founti P, Chatzikyriakidou A, Pappas T, Anastasopoulos E, Lambropoulos A, Ghosh A, Shetty R, Porporato N, Saravanan V, Venkatesh R, Shivkumar C, Kalpana N, Sarangapani S, Kanavi MR, Beni AN, Yazdani S, Lashay A, Naderifar H, Khatibi N, Fea A, Lavia C, Dallorto L, Rolle T, Frezzotti P, Paoli D, Salvi E, Manunta P, Mori Y, Miyata K, Higashide T, Chihara E, Ishiko S, Yoshida A, Yanagi M, Kiuchi Y, Ohashi T, Sakurai T, Sugimoto T, Chuman H, Aihara M, Inatani M, Miyake M, Gotoh N, Matsuda F, Yoshimura N, Ikeda Y, Ueno M, Sotozono C, Jeoung JW, Sagong M, Park KH, Ahn J, Cruz-Aguilar M, Ezzouhairi SM, Rafei A, Chong YF, Ng XY, Goh SR, Chen Y, Yong VHK, Khan MI, Olawoye OO, Ashaye AO, Ugbede I, Onakoya A, Kizor-Akaraiwe N, Teekhasaenee C, Suwan Y, Supakontanasan W, Okeke S, Uche NJ, Asimadu I, Ayub H, Akhtar F, Kosior-Jarecka E, Lukasik U, Lischinsky I, Castro V, Grossmann RP, Sunaric Megevand G, Roy S, Dervan E, Silke E, Rao A, Sahay P, Fornero P, Cuello O, Sivori D, Zompa T, Mills RA, Souzeau E, Mitchell P, Wang JJ, Hewitt AW, Coote M, Crowston JG, Astakhov SY, Akopov EL, Emelyanov A, Vysochinskaya V, Kazakbaeva G, Fayzrakhmanov R, Al-Obeidan SA, Owaidhah O, Aljasim LA, Chowbay B, Foo JN, Soh RQ, Sim KS, Xie Z, Cheong AWO, Mok SQ, Soo HM, Chen XY, Peh SQ, Heng KK, Husain R, Ho SL, Hillmer AM, Cheng CY, Escudero-Domínguez FA, González-Sarmiento R, Martinon-Torres F, Salas A, Pathanapitoon K, Hansapinyo L, Wanichwecharugruang B, Kitnarong N, Sakuntabhai A, Nguyn HX, Nguyn GTT, Nguyn TV, Zenz W, Binder A, Klobassa DS, Hibberd ML, Davila S, Herms S, Nöthen MM, Moebus S, Rautenbach RM, Ziskind A, Carmichael TR, Ramsay M, Álvarez L, García M, González-Iglesias H, Rodríguez-Calvo PP, Fernández-Vega Cueto L, Oguz Ç, Tamcelik N, Atalay E, Batu B, Aktas D, Kasım B, Wilson MR, Coleman AL, Liu Y, Challa P, Herndon L, Kuchtey RW, Kuchtey J, Curtin K, Chaya CJ, Crandall A, Zangwill LM, Wong TY, Nakano M, Kinoshita S, den Hollander AI, Vesti E, Fingert JH, Lee RK, Sit AJ, Shingleton BJ, Wang N, Cusi D, Qamar R, Kraft P, Pericak-Vance MA, Raychaudhuri S, Heegaard S, Kivelä T, Reis A, Kruse FE, Weinreb RN, Pasquale LR, Haines JL, Thorsteinsdottir U, Jonasson F, Allingham RR, Milea D, Ritch R, Kubota T, Tashiro K, Vithana EN, Micheal S, Topouzis F, Craig JE, Dubina M, Sundaresan P, Stefansson K, Wiggs JL, Pasutto F, Khor CC. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. Nat Genet. 2017;49:993-1004.
12. Forsius H, Forsman E, Fellman J, Eriksson AW. Exfoliation syndroma: frequency, gender distrubition and association with climatically induced alterations of the cornea and conjunctiva. Acta Ophtalmol Scan. 2002;80:478- 484.
13. Kozobolis VP, Papatzanaki M, Vlachonikolis IG, Pallikaris IG, Tsambarlakis IG. Epidemiology of pseudoexfoliation in the island of Crete (Greece). Acta Ophthalmol Scand. 1997;75:726-729.
14. Cahill M, Early A, Stack S, Blayney AW, Eustace P. Pseudoexfoliation and sensorineural hearing loss. Eye (Lond). 2002;16:261-266.
15. Jonas JB, Nangia V, Matin A, Bhojwani K, Sinha A, Khare A, Agarwal S, Bhate K. Pseudoexfoliation: normative data and associations. The Central India Eye and Medical Study. PloS One. 2013;8:76770.
16. Akarsu C, Unal B. Cerebral haemodynamics in patients with pseudoexfoliation glaucoma. Eye (Lond). 2005;19:1297-1300.
17. Ulus T, Nadir A, Yaz YA, Ozdemir AO, Mutlu F, Yazici HU, Cavusoglu Y, Yildirim N. Cardiovascular involvement in patients with pseudoexfoliation syndrome. J Cardiovasc Med (Hagerstown) 2013;14:587-592.
18. Kovac B, Vukosavljevic M, Janicijevic MP, Resan M, Jankovic J. The prevalence of pseudoexfoliation syndrome and possible systemic associations in patients scheduled for cataract surgery at the Military Medical Academy in Belgrade. Vojnosanitetski Pregl. 2014;71:839-844.
19. Schumacher S, Schlötzer-Schrehardt U, Martus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2001;357:359-360.
20. Janciauskiene S, Krakau T. Alzheimer’s peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome. Doc Ophthalmol. 2003;106:215-223.
21. Cumurcu T, Cumurcu BE, Celikel FC, Etikan I. Depression and anxiety in patients with pseudoexfoliative glaucoma. Gen Hosp Psychiatry. 2006;28:509- 515.
22. Yildirim N, Yasar E, Gursoy H, Colak E. Prevelance of pseudoexfoliation syndrome and its association with ocular and systemic disease in Eskişehir, Turkey. Int J Ophtalmol. 2017;10:128-134.
23. Yalaz M, Othman I, Nas K, Eroğlu A, Homurlu D, Çikintas Z, Ashouri A. The frequency of pseudoexfoliation syndrome in the eastern Mediterranean area of Turkey. Acta Ophthalmol (Copenh). 1992;70:209-213.
24. Alpay H, Ersoy G. Psödoeksfoliasyon sendromu (İstatistiksel bir çalışma). Turk J Ophthalmol. 1989;19:63-66.
25. Cumurcu T, Kilic R, Yologlu S. The frequency of pseudoexfoliation syndrome in the middle Black Sea region of Turkey. Eur J Ophthalmol. 2010;20:1007- 1011.
26. Gunes A, Yasar C, Tok L, Tok O. Prevalence of pseudoexfoliation syndrome in Turkish patients with senile cataract. Semin Ophthalmol. 2017;32:297-301.
27. Thomas AJ, Kalaria RN, T O’Brien JT. Depression and vascular disease: what is the relationship? J Affect Disord. 2004;79:81-95.
28. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54:915-922.
29. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
30. Erb C, Batra A, Lietz A, Bayer AU, Flammer J, Thiel HJ. Psychological characteristics of patients with normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1999;237:753-757.
31. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
32. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:676-692.
33. Elbi H. Kronik hastalık ve depresyon. J Clin Psy. 2008;11:3-18.
34. Hayward C. Psychiatric illness and cardiovascular disease risk. Epidem Rev. 1995;17:129-138.
35. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069-1078.
36. Mancuso CA, Peterson MG, Charlson ME. Effects of depressive symptoms on health-related quality of life in asthma patients. J Gen Intern Med. 2000;15:301-310.
37. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C, Gershenson DM. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78:302-308.
38. Tijani M, Albaroudi N, Boutimzine N, Cherkaoui O, Laghmari M. Prevalence of exfoliation syndrome and cardiovascular diseases in patients scheduled for cataract surgery. J Fr Ophtalmol. 2017;40:623-628.
39. Shazly TA, Farrag AN, Kamel A, Al-Hussaini AK. Prevalance of pseudoexfoliation syndrome and pesudoexfoliation glaucoma in upper Egypt. BMC Opthalmol. 2011;11:18.
40. Turacli ME, Ozdemir FA, Tekeli O, Gökcan K, Gerçeker M, Dürük K. Sensorineural hearing loss in pseudoexfoliation. Can J Ophtalmol. 2007;42:56-59.

APA	YAŞAR E, yildirim n, Atalay E (2019). Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. , 1 - 5. 10.4274/tjo.galenos.2018.06887
Chicago	YAŞAR Erdoğan,yildirim nilgün,Atalay Eray Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. (2019): 1 - 5. 10.4274/tjo.galenos.2018.06887
MLA	YAŞAR Erdoğan,yildirim nilgün,Atalay Eray Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. , 2019, ss.1 - 5. 10.4274/tjo.galenos.2018.06887
AMA	YAŞAR E,yildirim n,Atalay E Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. . 2019; 1 - 5. 10.4274/tjo.galenos.2018.06887
Vancouver	YAŞAR E,yildirim n,Atalay E Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. . 2019; 1 - 5. 10.4274/tjo.galenos.2018.06887
IEEE	YAŞAR E,yildirim n,Atalay E "Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı." , ss.1 - 5, 2019. 10.4274/tjo.galenos.2018.06887
ISNAD	YAŞAR, Erdoğan vd. "Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı". (2019), 1-5. https://doi.org/10.4274/tjo.galenos.2018.06887

APA	YAŞAR E, yildirim n, Atalay E (2019). Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. Türk Oftalmoloji Dergisi, 49(1), 1 - 5. 10.4274/tjo.galenos.2018.06887
Chicago	YAŞAR Erdoğan,yildirim nilgün,Atalay Eray Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. Türk Oftalmoloji Dergisi 49, no.1 (2019): 1 - 5. 10.4274/tjo.galenos.2018.06887
MLA	YAŞAR Erdoğan,yildirim nilgün,Atalay Eray Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. Türk Oftalmoloji Dergisi, vol.49, no.1, 2019, ss.1 - 5. 10.4274/tjo.galenos.2018.06887
AMA	YAŞAR E,yildirim n,Atalay E Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. Türk Oftalmoloji Dergisi. 2019; 49(1): 1 - 5. 10.4274/tjo.galenos.2018.06887
Vancouver	YAŞAR E,yildirim n,Atalay E Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı. Türk Oftalmoloji Dergisi. 2019; 49(1): 1 - 5. 10.4274/tjo.galenos.2018.06887
IEEE	YAŞAR E,yildirim n,Atalay E "Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı." Türk Oftalmoloji Dergisi, 49, ss.1 - 5, 2019. 10.4274/tjo.galenos.2018.06887
ISNAD	YAŞAR, Erdoğan vd. "Psödoeksfoliasyon Sendromu ve Antidepresan İlaç Kullanımı". Türk Oftalmoloji Dergisi 49/1 (2019), 1-5. https://doi.org/10.4274/tjo.galenos.2018.06887